• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Addex Therapeutics Ltd

    9/23/25 6:09:06 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email
    6-K 1 f6k_092325.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of September 2025

    Commission File Number: 001-39179

    Addex Therapeutics Ltd
    (Translation of registrant's name into English)

    Chemin des Mines 9,
    CH-1202 Geneva,
    Switzerland

    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]


     

    On September 23, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    (c) Exhibit 99.1. Press release dated September 23, 2025

    INCORPORATION BY REFERENCE

    Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Addex Therapeutics Ltd    
      (Registrant)
       
      
    Date: September 23, 2025     /s/ Tim Dyer    
      Tim Dyer
      Chief Executive Officer
      


    EXHIBIT INDEX

    Exhibit Number Description
       
    99.1 Press release dated September 23, 2025

    Get the next $ADXN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN

    DatePrice TargetRatingAnalyst
    7/31/2024$30.00Neutral → Buy
    H.C. Wainwright
    2/11/2022$28.00 → $21.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADXN
    SEC Filings

    View All

    SEC Form 6-K filed by Addex Therapeutics Ltd

    6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

    9/30/25 6:01:20 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Addex Therapeutics Ltd

    6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

    9/23/25 6:09:06 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Addex Therapeutics Ltd

    6-K - Addex Therapeutics Ltd. (0001574232) (Filer)

    6/30/25 6:05:06 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

    Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic

    9/30/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

    Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025. Tit

    9/26/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Appoints Bank of New York Mellon as Depositary Bank

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.  The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a

    9/23/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Addex Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Addex Therapeutics from Neutral to Buy and set a new price target of $30.00

    7/31/24 6:43:32 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Addex Therapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $21.00 from $28.00 previously

    2/11/22 6:28:07 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Addex Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $28.00

    4/21/21 6:28:54 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    Leadership Updates

    Live Leadership Updates

    View All

    Addex Appoints Bank of New York Mellon as Depositary Bank

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.  The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a

    9/23/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

    Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. "It's great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex

    8/2/21 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    Financials

    Live finance-specific insights

    View All

    Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

    Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic

    9/30/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

    Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025. Tit

    9/26/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

    Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators

    6/19/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Addex Therapeutics Ltd

    SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)

    8/14/24 8:12:35 PM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Addex Therapeutics Ltd

    SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)

    8/5/24 9:00:10 PM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Addex Therapeutics Ltd (Amendment)

    SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)

    12/8/23 2:11:53 PM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care